A Treatment Option for Metastatic Colorectal Cancer Patients with BRAFV600E Mutation in Singapore
- Written by Reporters
Targeted therapy regimen, BRAFTOVI® (encorafenib) in combination with cetuximab, included on MOH Cancer Drug List, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer who have received prior systemic therapy.
SUMMARY OF KEY POINTS
- BRAFTOVI in combination with cetuximab has been included on MOH CDL, for...